Radiochemistry, Department of Applied Chemistry, Necsa, South African Nuclear Energy Corporation Ltd., Pretoria, South Africa.
Anal Chim Acta. 2012 Jun 12;730:66-70. doi: 10.1016/j.aca.2011.10.068. Epub 2011 Nov 15.
The stability and in vivo robustness of [(177)Lu]Lu-DOTP as a potential bone-targeting radiopharmaceutical was determined with the aid of thermodynamic blood plasma modeling simulations. Glass electrode potentiometry was employed to measure the stability constants of the complexes of Lu(3+) with DOTP. Similarly, the complexes of DOTP with a selection of the important physiological metal ions: Ca(2+), Mg(2+), and Cu(2+) were determined, representing the typical interactions that the ligand would encounter upon administration. This made possible the construction of a blood plasma model of DOTP, aiding in establishing the potential susceptibility of the radiopharmaceutical. The ligand binds predominantly to calcium in vivo, accounting for 59.6% of that initially introduced as a component of the Lu-DOTP complex. Furthermore, due to a preference of the DOTP to bind to Cu(2+) it causes mobilization of the ions in blood plasma, and would therefore indicate a deficiency if the ligand is administered at a concentration of 8.5 × 10(-5) mol dm(-3). The lutetium-ions are preferentially bound to DOTP, with as much as 98.1% of the Lu(3+) occupying the ligand under physiological conditions.
[(177)Lu]Lu-DOTP 作为一种潜在的骨靶向放射性药物的稳定性和体内稳定性,借助热力学血浆建模模拟来确定。玻璃电极电位法用于测量 Lu(3+)与 DOTP 配合物的稳定常数。同样,测定了 DOTP 与一些重要生理金属离子(Ca(2+)、Mg(2+)和 Cu(2+))的配合物,代表了配体在给药时可能遇到的典型相互作用。这使得 DOTP 的血浆模型的构建成为可能,有助于确定放射性药物的潜在敏感性。该配体在体内主要与钙结合,占最初作为 Lu-DOTP 配合物一部分引入的钙的 59.6%。此外,由于 DOTP 优先与 Cu(2+)结合,它会导致血浆中离子的移动,如果配体以 8.5×10(-5)mol dm(-3)的浓度给药,则会表明存在缺乏。镥离子优先与 DOTP 结合,在生理条件下,多达 98.1%的 Lu(3+)占据配体。